NRAS somatic mutation testing
Over 50% of all colorectal cancers show mutations in one of the RAS genes, KRAS or NRAS of which around 1-6% of the mutations occur in NRAS gene alone. Anti-EGFR antibody (cetuximab and
panitumumab) therapy when given in combination with chemotherapy shows reduced efficacy in tumors harboring mutations in KRAS and NRAS genes.
Centogene offers multiple screening tests for targeted and general screening of mutations in NRAS gene to suit the recommendations of international guidelines.
A. Hot spot targeted mutation testing
c.181C>A/p.Q61K (27%), c.182A>G/p.Q61R (17%), c.35G>A/p.G12D (16%) and c.34G>T /p.G12C (11%) are the most frequent mutations present in NRAS-mutated tumors. For rapid and sensitive screening of these mutations, Centogene offers quantitative PCR based approach to selectively screen or monitor
individual mutations down to 0,05% allele frequency.
B. Full gene testing
Testing of complete coding region of NRAS gene is offered through Next Generation Sequencing that can detect mutations at allele frequency down to 5% in tumor samples.
C. Panel testing
For general screening of somatic mutations, NRAS exons are also a part of broader multi-gene panels like Cancer Hotspots Panel (detects 35 described mutations in NRAS gene along with commonly described mutations in 49 other oncogenes), Myeloid Tumor Panel (covers Exon 2 and Exon 3 of NRAS along with selective targeted regions in 53 other oncogenes and tumor suppressor genes involved in hematological malignancies) or Solid Tumor Panel (100% of the coding region of NRAS gene is covered along with over 95% coverage of coding regions of 61 other tumor related genes) that are readily available on Centogene website.
D. Microarray testing
Detection of 7 most important somatic mutations (including c.34G>A/T, c.35G>A/T, c.181C>A and c.182A>T/G,) in NRAS at >30% allele frequency is also supported by our CentoArrayOnco where one can combine detection of selective actionable somatic mutations with copy number variations across
900 oncogenes and tumor related genes in tumor samples. This array includes apart from NRAS,
67 mutations in 8 other oncogenes.
Please refer to preferred test(s) on our test catalogue or ask our customer relations team for more specific information. We are constantly developing new tests. If your preferred test is not listed on the webpage, please contact us directly. We will be happy to assist you find the best possible solution for your patient.